Iowa Medicaid Pharmaceutical and Therapeutics Committee
Minutes

Date: September 10, 2009

Chair: Susan Purcell, R.Ph.

Time: 9:37 a.m. to 11:56 a.m.

Location: Capitol Room 22, Des Moines, Iowa

Committee Members Present: Bruce Alexander, R.Ph., Pharm.D., BCPP; Matthew Osterhaus, R.Ph.; Susan Purcell, R.Ph, CGP; Hayley L. Harvey, DDS, MS; Mary Larew, M.D. (who left at 11:10); Charles Wadle, D.O.; and Carole Frier, D.O.

Iowa DHS Staff Present: Susan Parker, Pharm.D., Pharmacy Consultant; and Brad Horn, Assistant District Attorney.

Iowa Medicaid Enterprise (IME) Staff Present: Tim Clifford, M.D.; John Grotton, R.Ph.; Sandy Pranger, R.Ph.; Erin Halverson, R.Ph.; and Melissa Biddle.

Chairperson Sue Purcell called the meeting to order.

I. Sue Purcell asked that each committee, DHS staff, and IME staff member introduce themselves to the public. The June 11, 2009 open session minutes were reviewed. Matt Osterhaus made the motion to approve the minutes. Bruce Alexander seconded the motion. The motion passed with no objections. Matt Osterhaus nominated Sue Purcell for chairperson, and Bruce Alexander seconded. Sue Purcell nominated Matt Osterhaus as Vice-Chairperson, and Carole Frier seconded. Chuck Wadle moved to close nominations, and Bruce Alexander seconded. All members were in favor of these nominations. The committee also updated their annual conflict of interest and confidentiality forms.

II. PDL (Dr. Clifford): The State has just finished negotiations over the course of the summer, and the PDL will remain fairly stable. More specifics were given to the committee during the Closed Session. There might be significant changes to two major categories.

III. PA Criteria/Pro-DUR Edits (Susan Parker): The August 12th letter to DHS from the DUR Commission contained newly proposed criteria for thrombopoietin receptor agonists, and summarized the Commission's views on changing the Synagis PA criteria to match the new Red Book guidelines for RSV prevention. The September 3rd letter outlined the recommended prior authorization criteria for Uloric, as well as the Commission's second review of the new Red Book guidelines. There was also a letter dated September 3rd which summarized the DUR Commission referral of ophthalmic fluoroquinolones to the P&T Committee, in the hopes of making those drugs non-preferred so they would not be misused as a first line agent in treating bacterial conjunctivitis. The P&T Committee asked that a note notifying providers of the shortage of erythromycin ophthalmic ointment be included on the informational letter that will be sent to providers.

IV. Drug Rebate Issues: None at this time.

V. Legislation: A Request for Proposal (RFP) document was scheduled to be released September 17th for IME services.

VI. The public speakers were:

SPEAKER	SUBJECT
Andrew Korotzer from Strativa Pharmaceuticals	Nascobal Nasal Spray
Felicia Williams from Merck	Januvia, Janumet, and Singulair
Ruth Neiman from UCB, Inc.	Cimzia
Pauline Patrick from Forest Labs	Savella
David Olson from Teva Pharmacueticals	LoSeasonique
Maureen Kubacki from Ortho-Biotec	Simponi
Dan Baldi from Janssen Ortho	Nucynta
Jennifer Stoffel from Janssen Ortho	Nucynta

At 10:28, motion to go to closed session was made by Matt Oserhaus and seconded by Sue Purcell. The motion passed with unanimous approval. Open session resumed at 11:23.

VII. PDL Discussion and Deliberation (Dr. Clifford): It was recommended that Accutane be removed from the PDL since it has been discontinued by the manufacturer; isotretinoin would then become preferred with conditions. Claims for brand-name Accutane will continue to pay for current prior authorizations until the supply is exhausted by the pharmacy. Monopril HCT will also be removed from the PDL due to its discontinuation. It was recommended to change the status of cefdinir to preferred on the PDL to maximize cost savings to the program; Omnicef is already preferred on the PDL. Additionally, it was recommended to change the status of Cellcept to non-recommended and require a Selected Brand Name Drug PA to maximize cost savings to the program. (Mycophenolate is being added as recommended.) It was recommended to change the status of Prilosec OTC to non-covered and legend Omeprazole to preferred with conditions, effective November 1, 2009, to maximize costs savings to the program. It was recommended to change the status of Neoral to non-recommended and require a Selected Brand Name Drug PA to maximize cost savings to the program. (Cyclosporine modified is already listed as recommended.) Dr. Frier asked that a letter be sent to the providers that levels needed to be monitored more closely given this change to generic medications. Lastly, it was recommended to add a Selected Brand Name Drug PA requirement to Retrovir (non-recommended) to maximize cost savings to the program and clarify PA requirement. (Zidovudine is already listed as recommended.) Symbyax was also recommended to be non-preferred; existing users will be grandfathered. Carole Frier motioned to accept these recommendations, and Matt Osterhaus seconded. The motion passed unanimously.

VIII. Newly Released Drugs: Cimzia (prefilled Syringe), Nuvigil, and Simponi were all recommended to be non-preferred with conditions. However, Cimzia may have a different PDL classification recommendation at the November meeting, as its drug class is up for review. Nucynta, Samsca, and Ulesfia Lotion were recommended to be non-preferred.

Savella was recommended to be non-preferred with conditions, with an additional recommendation that the Drug Utilization Review (DUR) Commission develop prior authorization criteria. Bruce Alexander motioned to accept these recommendations, and Chuck Wadle seconded. The motion passed with no objections or abstentions.

IX. Newly Released Generic Drugs and New Dosage Forms: In the newly released generics, it was recommended that calcitonin-salmon spray, carbamazepine er, liothyronine, malathion, and next choice be non-preferred on the PDL. Also, bicalutamide will be non-recommended, mycophenolate recommended, and risperidone odt non-preferred with conditions. As for new dosage forms, Lamictal XR was recommended to be non-preferred with conditions, and Vectical non-preferred. LoSeasonique will be non-preferred just like Seasonique. Matt Osterhaus motioned to accept these recommendations, and Bruce Alexander seconded.

A motion was made by Matt Osterhaus to adjourn the meeting. Chuck Wadle seconded the motion. All in attendance approved. The meeting adjourned at 11:56 a.m. The next scheduled meeting will be March 11, 2010.